Live on Bloomberg TV

00:00AMID THIS BUSY DAY AND AFTERNOON, BEN OAKES JOINS US NOW. REMIND US WHAT YOU ARE TELLING AT THIS EVENT, THE POWER OF THIS TECHNOLOGY. ULTIMATELY, WHAT -- ULTIMATELY, YOUR EX EDITOR. BEN: WHAT WE ARE TALKING ABOUT AT THE AMERICAN SOCIETY FOR CELL AND GENE THERAPY WEIGHT OF TODAY IS LAYING OUT OUR CRISPER BY DESIGN APPROACH, AN APPROACH I HAVE BEEN PIONEERING WITH THE COFOUNDER OF SCRIBE. OUR APPROACH HAS BEEN TO USE HOLISTIC MOLECULAR ENGINEERING FOR THE ABILITY TO CHANGE THESE CRISPER MOLECULAR MACHINES AT EVERY LOCATION TO CREATE MORE ACTIVE AND SPECIFIC AND SAFER THERAPEUTICS. ONE OF OUR SCIENTISTS WILL BE LAYING THAT OUT TODAY. CAROLINE: YOU HAVE DESIGNED BY APPROACH WORKING WITH PREVAIL ELI LILLY. EXCLUSIVE RIGHTS TO FOCUS ON YOUR TECHNOLOGY AND USE IT WITHIN A NEUROLOGICAL AND NEUROLOGICAL -- NEUROMUSCULAR CONTEXT. WHY DO THE DEAL NOW WITH THIS PARTICULAR COMPANY? BEN: A COUPLE REASONS HERE. FIRST, OBVIOUSLY, OUR TECHNOLOGIES HAVE CONTINUED TO ADVANCE. WE HAVE BEEN DEMONSTRATING THEIR ABILITY TO BE DELIVERED INTO THESE ORGAN SYSTEMS, NAMELY NEUROLOGICAL, NEUROMUSCULAR DISEASES. MORE SPECIFICALLY, I THINK IT REPRESENTS A CHANGE IN THE FIELD IN THINKING ABOUT HOW WE CAN START TO APPLY THESE TECHNOLOGIES FOR MORE COMPLICATED AND MORE DIFFICULT TO TREAT DISORDERS. CAROLINE: SINCE OF TIMING HERE, BECAUSE MUCH ENTHUSIASM AROUND CRISPER AND HOW IT CAN CHANGE MEDICINE. WILL THIS HAPPEN IN THE NEXT YEAR, THE NEXT 10 YEARS? BEN: I THINK IT IS SOMEWHERE IN BETWEEN THE TWO. THERE IS STILL A LOT OF WORK TO DO. I DO NOT WANT TO SAY THIS IS SIMPLE. WE HAVE SEEN CRISPER BOTH FROM PUBLICATION WITHIN THE PAST DECADE TO MAKING HUGE DIFFERENCES IN PATIENTS MORE RECENTLY. THAT IS INCREDIBLY RAPID. THAT DEMONSTRATES THE POWER OF THIS TECHNOLOGY. THAT IS THE FIRST GENERATION. WHAT WE ARE BUILDING, LIGHT YEARS AHEAD OF WHAT HAS COME BEFORE. WE ARE EXCITED ABOUT OUR ABILITY TO DO THIS RAPIDLY AND INTO DISEASES AT A MUCH MORE BROADER SCALE. CAROLINE: CAN YOU GIVE US A SENSE OF HOW TO DO THAT WITHIN AMERICA, VIS-À-VIS OTHER COUNTRIES? HOW HAS THIS TECHNOLOGY MADE THE ABILITY TO START TO QUICKLY TARGET THESE ILL AND -- ILLNESSES? WHERE IS THE MOST PRACTICAL AND EFFICIENT TO DO IT? BEN: THAT IS A DEEP QUESTION, ONE THAT HAS MANY LAYERS. IF WE ARE TALKING MORE BASIC TECHNOLOGY BUILDING, THE UNITED STATES HAS INCREDIBLY POWERFUL UNIVERSITIES WE GET TO WORK WITH AND WE DO QUITE REGULARLY. WE HAVE A CLOSE COLLABORATION WITH UC BERKELEY, WHERE JENNIFER WORKS AND THE INNOVATIVE GENOMICS INSTITUTE. REGULATORY AND MOVING BEYOND DUST WILL DO THESE

No schedule data available.

BTV Channel FinderWatch BTV in your area

Scribe Inks CRISPR Gene-Editing Deal with Prevail

CRISPR pioneer Jennifer Doudna's company Scribe Therapeutics inked a major deal with Prevail Therapeutics potentially worth $1.5 billion to create genetic medicines for neurological and neuromuscular diseases. Scribe CEO Ben Oakes joins Caroline Hyde for more. (Source: Bloomberg)

More From Bloomberg Technology
All episodes and clips

Bloomberg Markets
"Bloomberg Markets" is focused on bringing you the most important global business and breaking markets news and information as it happens.
More episodes and clips